Corrigendum

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi-Cheng Wang, Bo-Ya Xiao, Peng-Cheng Li, Bo-Hua Kuang, Wang-Bing Chen, Pin-Dong Li, Guo-He Lin, and Quentin Liu

1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
2Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China
3Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
4State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China

Correspondence should be addressed to Bi-Cheng Wang; bcsnowell@163.com

Received 17 February 2021; Accepted 17 February 2021; Published 26 February 2021

Copyright © 2021 Bi-Cheng Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis” [1], the information was omitted in the Acknowledgments section: the Hubei Provincial Natural Science Foundation (grant number: 2020CFB397 to Bi-Cheng Wang). The corrected section appears as follows:

Acknowledgments

The authors thank the Bi-Cheng Wang studio for helping to offer ideas and improve grammar and spelling. This study was supported by the Independent Innovation Foundation of Wuhan Union Hospital (grant number: 2019-109 to Bi-Cheng Wang) and the Hubei Provincial Natural Science Foundation (grant number: 2020CFB397 to Bi-Cheng Wang).

References